Inclusion Criteria:

1. Patients must have histologically-proven prostate cancer stage T1c -T3a (UICC 1997).

2. Patients with clinically organ-confined disease must meet the Canadian consensus
definition of intermediate risk disease (i.e any one or more of: CS = T2b [UICC1997
= bilateral palpable intra-capsular disease], GS = 7, or iPSA >10 and 20).

3. Patients with Gleason sum 8 and/or PSA > 20 must have a CT pelvis, and nuclear
medicine bone scan showing no evidence of nodal (N0) or distant metastases (M0).

4. Registration must occur within 36 weeks of biopsy.

5. Patients with clinical or pathological evidence of seminal vesicle invasion (stage
T3b) or involvement of adjacent pelvic organs/structures (stage T4) are not eligible.

6. Pre-intervention PSA must not exceed 40 ng ml-1.

7. Patients must have a chest x-ray and the following blood tests within four weeks of
registration: PSA, PAP, testosterone, CBC, electrolytes, BUN, creatinine, AST, LDH
and alkaline phosphatase. Patients with values for one or more of these tests that
fall outside the normal range will not necessarily be ineligible, however, their
eligibility will need to be reviewed by the study coordinator.

8. Patients must have an ECG within four weeks of registration. Patients with ECGs
judged to be significantly abnormal require a consultation with a cardiologist to
ascertain their suitability for general or spinal anesthesia.

9. Patients judged clinically to have a prostate volume > 65 cm3 prior to starting
androgen suppression must have a transrectal ultrasound for volume estimation.
Patients with TRUS prostate volumes > 75 cm3 prior to starting androgen suppression
are not eligible for the study.

10. Patients may have been started on neoadjuvant androgen suppression prior to
registration provided:

- there is documentation of pre-treatment PSA and

- in the case of patients with iPSA >20 and/or Gleason sum 8, a bone scan and CT
pelvis were done prior to or within 4 weeks after starting neoadjuvant androgen
suppression.

11. Patients must not have received prior surgical treatment for prostate cancer
including transurethral resection of the prostate (TURP), transurethral resection of
the bladder neck (TURB), cryotherapy, laser ablation, or microwave therapy.

12. Patients should have an estimated life expectancy of at least 5 years with an ECOG
performance status of 0-2.

13. Patients may not have received prior radiation therapy to the pelvis.

14. Patients must be fit for general or spinal anesthetic.

15. Patients on Coumadin therapy must be able to stop the therapy safely for at least 12
days. Documentation as to the safety of such an interruption in anticoagulation
therapy must be provided by an appropriate specialist physician (usually a
cardiologist or hematologist).

16. Patients must be judged to have no contraindication to high dose pelvic irradiation
or LHRH agonist therapy.

17. Cancer survivors are eligible providing that all three of the following criteria are
met:

- The patient has undergone potentially curative therapy for all prior
malignancies.

- There has been no evidence of recurrence for at least five years following
potentially curative therapy. (For non-melanoma skin cancer the five-year
requirement does not apply.)

- The patient is considered by the treating physician to be at low risk of
recurrence from prior malignancies.